INTI Stock Overview
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Inhibitor Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.088 |
| 52 Week High | US$0.30 |
| 52 Week Low | US$0.013 |
| Beta | -0.77 |
| 1 Month Change | 28.84% |
| 3 Month Change | 81.79% |
| 1 Year Change | 193.33% |
| 3 Year Change | 17.33% |
| 5 Year Change | 30.56% |
| Change since IPO | -99.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| INTI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.6% | 2.7% | 0.3% |
| 1Y | 193.3% | 2.9% | 24.2% |
Return vs Industry: INTI exceeded the US Biotechs industry which returned 1.2% over the past year.
Return vs Market: INTI exceeded the US Market which returned 22.8% over the past year.
Price Volatility
| INTI volatility | |
|---|---|
| INTI Average Weekly Movement | 47.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INTI's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine INTI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 6 | Frank O'Donnell | inhibitortx.com |
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019.
Inhibitor Therapeutics, Inc. Fundamentals Summary
| INTI fundamental statistics | |
|---|---|
| Market cap | US$15.14m |
| Earnings (TTM) | -US$3.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.0x
P/E RatioIs INTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INTI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$3.03m |
| Earnings | -US$3.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INTI perform over the long term?
See historical performance and comparison